Strategic Acquisition Stryker’s acquisition of Amplitude Vascular Systems creates an expanded opportunity to engage a larger, established customer base in vascular interventions and to position Pulse IVL capabilities as a complementary technology within Stryker's MedSurg and vascular portfolio.

Targeted Market Fit AVS focuses on severely calcified arterial disease with a novel pulsatile IVL platform, aligning with high-need peripheral arterial disease segments where calcium burden complicates interventions—a compelling card to play with interventional cardiology and vascular surgery customers seeking safer, simpler lesion treatment.

Growth Momentum With a Series B financing history and recent large-scale acquisition activity valued at up to 835 million dollars, there is demonstrated investor and market interest; leverage this momentum to identify early-adopter hospitals and regional vascular labs prioritizing innovative calcification solutions.

Strategic Roles Key personnel appointments and clinical leadership, including a Vice President of Clinical Affairs, indicate a focus on clinical evidence generation and adoption; target clinical champions, KOLs, and procurement teams who influence device selection and training in AVS-adjacent accounts.

Integrated Solutions As part of a broader medical technology ecosystem, AVS patients and customers may benefit from bundled solutions, training, and service integration with Stryker platforms; approach enterprise customers with a value story that includes workflow efficiency, one-vendor support, and post-market surveillance collaboration.